首页|基于NF-κB信号通路探讨乌梅丸联合消痔灵治疗慢性放射性直肠炎作用机制

基于NF-κB信号通路探讨乌梅丸联合消痔灵治疗慢性放射性直肠炎作用机制

扫码查看
乌梅丸治疗慢性放射性直肠炎可能通过抑制核转录因子-κB(nuclear factor kappa-B,NF-κB)信号通路转导的上游调控点IκB激酶(IκB kinase,IKK),下调IκB蛋白磷酸化,进而抑制NF-κB活化,还可通过下调免疫性结肠炎结肠NF-κB表达,抑制白细胞介素(interleukin,IL)-1β的产生,减轻炎性反应;消痔灵灌肠治疗放射性直肠炎,可以有效降低炎性因子水平,提高临床疗效.乌梅丸联合消痔灵可以通过NF-κB抑制肠道炎性反应,对慢性放射性直肠炎有一定的疗效.但目前,国际与国内关于慢性放射性直肠炎的研究较少,分子结构尚不明确,诊断与治疗缺乏统一性,且乌梅丸组成众多,各方药具有多种药理作用,研究机制较为复杂.今后,需开展动物实验及循证医学研究,以进一步验证消痔灵联合乌梅丸治疗慢性放射性直肠炎的作用机制.
Study on the Mechanism of Action of Mume Pill Combined with Xiaozhiling in the Treatment of Chronic Radiation Proctitis Based on NF-κB Signaling Pathway
Mume Pill in the treatment of chronic radiation proctitis may inhibit the upstream regulatory point of nuclear factor kappa-B(NF-κB)signaling pathway transduction,down-regulate the phosphorylation of IκB protein,and then inhibit the activation of NF-κB.It can also down-regulate the expression of NF-κB in colon of immune colitis,inhibit the production of interleukin(IL)-1β,and reduce inflammatory response.Xiaozhiling(消痔灵,XZL)for enema in the treatment of radiation proctitis can effectively reduce the level of inflammatory factors and improve clinical efficacy.Mume Pill combined with XZL has a certain effect on chronic radiation proctitis by inhibiting intestinal inflammatory response through NF-κB.However,at present,there are few studies on chronic radiation proctitis at home and abroad,the molecular structure is not clear,and the diagnosis and treatment lack unity.Moreover,Mume Pill has many compo-nents,and each drug has a variety of pharmacological effects,and the research mechanism is complex.In the future,animal experiments and evidence-based medicine research are needed to further verify the mechanism of action of XZL combined with Mume Pill in the treatment of chronic radiation proctitis.

Mume PillXiaozhiling(消痔灵,XZL)chronic radiation enteritisNF-κB signaling pathwayTreatise on Cold Damage Dis-easesZhang Zhongjing

马玉婷、杜燕红、杨德群

展开 >

湖北中医药大学,湖北 武汉 430000

湖北中医药大学附属湖北省中医院,湖北 武汉 430000

乌梅丸 消痔灵 慢性放射性肠炎 NF-κB信号通路 《伤寒论》 张仲景

湖北省中医药管理局中医药指导性项目(2023-2024)

ZY2023F001

2024

河南中医
河南省中医药学会 河南中医学院

河南中医

影响因子:0.968
ISSN:1003-5028
年,卷(期):2024.44(5)
  • 43